Navigation Links
New molecule protects brain from detrimental effects linked to diabetes and high blood sugar
Date:1/28/2014

Researchers at the Hebrew university of Jerusalem have created a molecule that could potentially lower diabetic patients' higher risk of developing dementia or Alzheimer's disease.

Recent studies indicate that high levels of sugar in the blood in diabetics and non-diabetics are a risk factor for the development of dementia, impaired cognition, and a decline of brain function. Diabetics have also been found to have twice the risk of developing Alzheimer's disease compared to non-diabetics. Now, researchers from the Hebrew University of Jerusalem have found a potential neuro-inflammatory pathway that could be responsible for the increases of diabetics' risk of Alzheimer's and dementia. They also reveal a potential treatment to reverse this process.

The research group led by Prof. Daphne Atlas, of the Department of Biological Chemistry in the Alexander Silberman Institute of Life Sciences at the Hebrew University, experimented with diabetic rats to examine the mechanism of action that may be responsible for changes in the brain due to high sugar levels. The researchers found that diabetic rats displayed high activity of enzymes called MAPK kinases, which are involved in facilitating cellular responses to a variety of stimuli, leading to inflammatory activity in brain cells and the early death of cells.

The study shows that the diabetic rats given a daily injection of the sugar-lowering drug rosiglitazone for a month enjoyed a significant decrease in MAPK enzyme activity accompanied by a decrease in the inflammatory processes in the brain. According to the authors, this finding represents the first unequivocal evidence of a functional link between high blood sugar and the activation of this specific inflammatory pathway in the brain.

Using the diabetic rat model, they explored a novel approach that would lower the activation of these enzymes in the brain, and decrease neuronal cell death. In the last few years, Prof. Atlas developed a series of molecules that mimic the action of thioredoxin called thioredoxin-mimetic peptides (TXM), whose role is to protect the cells from early death through activating inflammatory pathways. The TXM peptides were effective in different animal models and were able to prevent the activation of the damaging MAPK kinases. Applied to the diabetic Zucker rats, one of the molecules, TXM-CB3, significantly reduced the activity of these enzymes, and lowered the accelerated brain cell death. These results indicate that the molecule managed to cross the blood-brain barrier and improve the condition of the brain cells, through lowering the inflammatory processes in the rats' brains, despite the high glucose levels afflicting the rats.

The Hebrew University's Prof. Atlas said: "This study paves the way for preventive treatment of damages caused by high sugar levels, and for reducing the risk of dementia and Alzheimer's disease in diabetics or people with elevated blood sugar levels. Following the successful animal testing of the molecule we developed, we hope to explore its potential benefit for treating cognitive and memory impairments caused by diabetes on humans."

The molecule is protected by a patent registered by Yissum Research Development Company, the technology transfer arm of the Hebrew University.

The study, "Thioredoxin-Mimetic peptide CB3 Lowers MAPKinsase activity in the Zucker Rat Brain," appeared in the journal Redox Biology, an official Journal of the Society for Free Radical Biology and Medicine and the Society for Free Radical Research-Europe.


'/>"/>

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-82844
The Hebrew University of Jerusalem
Source:Eurekalert  

Related biology news :

1. Programming smart molecules
2. Missing molecule in chemical production line discovered
3. New tool developed for profiling critical regulatory structures of RNA molecules
4. New microscope captures movements of atoms and molecules
5. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
6. SlipChip counts molecules with chemistry and a cell phone
7. Penn Dental Medicine team identifies molecule critical to healing wounds
8. Lawrence Livermore researchers unveil carbon nanotube jungles to better detect molecules
9. BUSM researchers identify molecule that could aid lung cancer detection, treatment
10. Biomolecules for the production line
11. MicroRNA molecule found to be a potent tumor-suppressor in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New molecule protects brain from detrimental effects linked to diabetes and high blood sugar
(Date:1/19/2017)... India , January 19, 2017 According to a ... Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is expected ... 2016 to 2022. In 2015, Asia-Pacific dominated the global ... and private sectors. Continue Reading ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... 2017   Instrument Business Outlook ( ... MN ) the 2016 Company of the ... newsletter tracking developments in the analytical and life ... consistently achieved outstanding technical, operational and financial results ... of IBO. "In 2016, Bio-Techne capitalized on opportunities ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... company announces significant growth last year adding 65 new US and international facilities ... Army medical centers as well as one of US largest imaging center chains. ...
(Date:1/23/2017)... 23, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... New Zealand based Phase 1 ... showed remarkable results in reducing inflamed protein biomarkers in ... It is believed that this is the first time ... type can be made between epigenetic regulation and its ...
(Date:1/23/2017)... Calif. , Jan. 23, 2017  Alkahest ... innovative treatments for neurodegenerative diseases and other age-related ... joined the company as Chief Medical Officer. In ... and clinical development activities at Alkahest and serve ... Jackson most recently served as Executive Director at ...
Breaking Biology Technology: